Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...
Employers added only 22,000 jobs in August, and the unemployment rate rose slightly to 4.3 percent. Revised data also showed that employment fell by 13,000 jobs in June, the first net loss since ...
The labor market showed signs of weakening, with 73,000 jobs added in July and gains for the previous two months revised significantly lower. Monthly change in jobs +73,000 jobs in July +300,000 ...
Apple has officially revealed that Japan's My Number Card can now be included in the Wallet app on iPhones with iOS 18.5 or later. The integration was first announced in May 2024. The new feature is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback